Cogley Brian 4

What Happened Brian Cogley, Chief Financial Officer of Coeptis Therapeutics Holdings, exercised 10,000 stock options on 2026-02-11 at an exercise price of $10.56 per share (total cost $105,600) and, on the same date, received a grant of 12,500 restricted shares issued at $0.00 as part of an option-exchange award.

Key Details

• Transaction date: 2026-02-11; filing date: 2026-02-13 (filed within the typical 2-business-day Form 4 window).
• Option exercise: 10,000 shares acquired at $10.56 each; total cash paid = $105,600. (Footnote F1: $10.56 is the exercise price.)
• Award/grant: 12,500 restricted shares issued at $0.00. (Footnote F2: restricted stock granted in exchange for surrendering underwater options under an option-exchange program.)
• Shares owned after the transaction: not specified in the provided report.
• No indication in the filing that shares were immediately sold (no cashless sale reported).

Context Exercising options is a way for insiders to convert vested options into common shares; the exercise here appears to be a straightforward cash exercise (the filer paid the exercise price). The restricted shares were issued as part of an option-exchange program, which is typically used to replace underwater options with restricted stock and does not by itself signal the insider’s market view. All items were acquisitions (not sales), but acquisitions can reflect a range of personal or tax-driven decisions rather than a predictive statement about the company’s stock.